UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D. C. 20549
____________
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act Of 1934
October
3, 2005
Date
of
Report (Date of earliest event reported)
___________________________________________________________
ACURA
PHARMACEUTICALS, INC.
(Exact
Name of Registrant as Specified in Charter)
___________________________________________________________
State
of New York
|
1-10113
|
11-0853640
|
(State
of Other Jurisdiction
|
(Commission
File Number)
|
(I.R.S.
Employer
|
of
Incorporation)
|
|
Identification
Number)
|
616
N. North Court, Suite 120
Palatine,
Illinois 60067
(Address
of principal executive offices) (Zip Code)
(847)
705-7709
(Registrant's
telephone number, including area code)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)
o
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act
(17CFR240.14d-2(b))
o
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e- 4(c))
Item
8.01 Other
Events
On
October 3, 2005, Acura Pharmaceuticals, Inc. (the "Company") issued a press
release announcing the Company's receipt of communication from the U.S. Food
and
Drug Administration ("FDA") requesting certain non-clinical studies relating
to
the Company's Product Candidate #2. A copy of the Company's Press Release
is
attached hereto as Exhibit 99.1.
Item
9.01 Financial
Statements and Exhibits.
Exhibit
99.1
|
Press
Release dated October 3, 2005 Announcing Receipt of FDA Communication.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
|
|
|
ACURA
PHARMACEUTICALS, INC. |
|
|
|
Date: October
3, 2005 |
By: |
/s/ Peter
A. Clemens |
|
Peter
A. Clemens |
|
Vice
President & Chief Financial
Officer |
EXHIBIT
INDEX
Exhibit
99.1
|
Press
Release dated October 3, 2005 Announcing Receipt of FDA Communication.
|